I'm thinking the range should hold, as long as Vascepa continues the general path we've seen up to this point and looks like it's heading towards the $80 M in sales rev mark by december or so
AMRN is down about 18% since they launched their drug, while the S&P moved up about 10% and while many other biotechs have been seeing deep double-digit gains
I am stating the obvious - the launch has been subpar up to this point and has disappointed shareholders and the market. If prescriptions slow down, the company's $1 B valuation will start to look quite lofty
but we'll have to see if this is a longer term trend or if this is a hiccup
Recent Questcor Short Squeeze Confirmed, Continuation Possible [View article]
Recent Questcor Short Squeeze Confirmed, Continuation Possible [View article]
it's fun!
Recent Questcor Short Squeeze Confirmed, Continuation Possible [View article]
Recent Questcor Short Squeeze Confirmed, Continuation Possible [View article]
data doesn't confirm any theories on the last 2 weeks, which were really odd
Amarin Stays Rangebound, Prescriptions Stagnate [View article]
Amarin Stays Rangebound, Prescriptions Stagnate [View article]
Amarin Stays Rangebound, Prescriptions Stagnate [View article]
Amarin Stays Rangebound, Prescriptions Stagnate [View article]
I am stating the obvious - the launch has been subpar up to this point and has disappointed shareholders and the market. If prescriptions slow down, the company's $1 B valuation will start to look quite lofty
but we'll have to see if this is a longer term trend or if this is a hiccup
Amarin Stays Rangebound, Prescriptions Stagnate [View article]
Amarin Stays Rangebound, Prescriptions Stagnate [View article]
Amarin Stays Rangebound, Prescriptions Stagnate [View article]
Amarin Stays Rangebound, Prescriptions Stagnate [View article]
The "real diligence" says that the launch isn't impressing anybody
Vivus Heats Up, Shorts Discouraged On Possible Bidding War [View article]
I'm trying to get in contact with First Manhattan, and I will see if I can reach alex denner too
Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground [View article]
at least not right now. If they do secure a partnership obviously this changes, but we'll see
Amarin Reports Solid Vascepa TRx Growth, Stock Holds Its Ground [View article]
I want to discuss what we know. assuming that amarin will secure a deal is why investors lost almost half of their money in Dec. 2012